Fish Oil for Cognitive Function, Sleep Quality, and Bone Density
NCT ID: NCT06614374
Last Updated: 2025-08-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
415 participants
INTERVENTIONAL
2020-10-10
2022-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Fish Oil-derived Omega-3 Fatty Acids on Gut Microbiota and Lipid Metabolome in Type 2 Diabetes Mellitus
NCT06061510
Effect of Fish Oil on Insulin Sensitivity
NCT01241474
N-3 Polyunsaturated Fatty Acids to Prevent and Treat Diabetic Neuropathy
NCT05145452
The Effects of Omega-3 Fatty Acids Supplementation on Endothelial Function and Inflammation
NCT01310270
Impact of n-3 Polyunsaturated Fatty Acids in a Protein-enriched Diet With Low GI in Type 2 Diabetes Patients
NCT01474603
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control group
Subjects will receive equivalent amounts of refined olive oil daily.
Refined olive oil
Participants in the control group will receive 4 g refined olive oil daily
Low-dose fish oil group
Subjects will receive four fish oil and refined olive oil mixed capsules containing 1.5 g of marine n-3 PUFAs (72% EPA and 28% DHA) per day
Low-dose fish oil capsules
Patients in the low-dose group will receive four fish-oil and refined olive oil mixed capsules containing 1.5 g of marine n-3 PUFAs per day.
High-dose fish oil group
Subjects will receive four fish oil capsules containing 3 g of marine n-3 PUFAs (72% EPA and 28% DHA) per day
High-dose fish oil capsules
Patients in the high-dose group will receive four fish oil capsules containing 3 g of marine n-3 PUFAs (72% EPA and 28% DHA) per day.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Low-dose fish oil capsules
Patients in the low-dose group will receive four fish-oil and refined olive oil mixed capsules containing 1.5 g of marine n-3 PUFAs per day.
High-dose fish oil capsules
Patients in the high-dose group will receive four fish oil capsules containing 3 g of marine n-3 PUFAs (72% EPA and 28% DHA) per day.
Refined olive oil
Participants in the control group will receive 4 g refined olive oil daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Between 40 and 75 years old (postmenopausal women);
* Have never used n-3 PUFA supplements before or have stopped using them for more than six months.
Exclusion Criteria
* Coronary heart disease, stroke, cancer, hepatic or kidney disease;
* Pregnancy or lactation;
* Allergy to fish;
* Have participated in other clinical trials in the last three months.
40 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jingjing Jiao
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jingjing Jiao
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lanxi Red Cross Hospital
Jinhua, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RCT_N3_SUPPLE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.